Not quite apples and apples drainer. Cu6 was dosing at suboptimal levels as a single agent and achieving said response. Zan was in combo at a dose they deemed at most efficacious.
cu6 want to dose cumulatively 48GBq vs what they got at undetectable, which is 16GBq. This is 33% less than what they're looking to dose as their desired dosing schedule.
With that said, achieving a CR in a terminal patient with multiple lines of treatment is a great response. Unfortunately still not within a scope of approval development plans.
Ann: Bisantrene Phase 2 AML Trial Successful Concludes, page-49
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.000(0.00%) |
Mkt cap ! $269.2M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.58 | $29.84K | 18.67K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 15247 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 1000 | 1 |
View Market Depth
| Last trade - 10.38am 11/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |